| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424146100 | Binds enzyme | 61 |
| 20090022732 | Crystal of a cytochrome-ligand complex and methods of use - The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome. | 01-22-2009 |
| 20090068194 | Antibodies and Their Use In The Treatment, Prevention and Diagnosis of a Disease Associated With SOD1 Abnormalities - The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human. | 03-12-2009 |
| 20090169564 | Stimulus Inducible Protein Kinase Complex and Methods of Use Therefor - Compositions and methods are provided for treating NF-κB-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-κB cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-κB activation. | 07-02-2009 |
| 20090175882 | METHODS AND COMPOSITIONS FOR TREATING HYPERALGESIA - This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific inhibitors to treat or alleviate pains mediated by noxious mechanosensation. | 07-09-2009 |
| 20090208510 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 08-20-2009 |
| 20100092480 | MODULATORS OF PROTEIN PHOSPHATASE 2A - Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) core, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A core is also provided. Compositions including mimetics and small molecules of the invention and, optionally, secondary agents may be used to treat disorders in which PP2A activity plays a contributing role. | 04-15-2010 |
| 20100098707 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 04-22-2010 |
| 20100196390 | AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES - The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease. | 08-05-2010 |
| 20100291099 | NOVEL 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 AND 32222 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 11-18-2010 |
| 20110059100 | C/CLP Antagonists And Methods Of Use Thereof - The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL-13 mediated inflammation. | 03-10-2011 |
| 20110104175 | METHODS OF TREATMENT FOR PULMONARY FIBROSIS - The invention relates to compositions and methods for treating fibrosing lung diseases, reducing pulmonary cytokine production in animals, treating bleomycin induced lung disease and treating cancer. Specifically, the present subject matter incorporates inactivation of the N-terminal site of an angiotensin-converting enzyme and/or administration of AcSDKP. | 05-05-2011 |
| 20110182907 | Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase I-Associated Diseases - The invention relates to antibodies against α-enolase I, their pharmaceutical compositions and diagnosis and treatment uses. Particularly, the invention provides polyclonal anti-α-enolase I antibodies and monoclonal single-chain variable fragment (scFv) anti-α-enolase antibodies, pharmaceutical compositions containing the same and their uses in uses in diagnosis and treatment of cancers, autoimmune disorders, ischemia and bacterial infection. | 07-28-2011 |
| 20110223177 | TREATMENT OF FIBROTIC EYE DISORDERS - Inhibitors of myosin activity are used to treat or prevent a fibrotic disorder of the eye, for example posterior capsule opacification (PCO). | 09-15-2011 |
| 20110250207 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 10-13-2011 |
| 20110262450 | MODULATORS OF MONOGLYCERIDE LIPASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of monoglyceride lipase (MGLL), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 10-27-2011 |
| 20110262451 | MODULATORS OF ISOVALERYL-COENZYME A DEHYDROGENASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 10-27-2011 |
| 20110274699 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF - Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof. | 11-10-2011 |
| 20110305706 | Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta - The present invention relates to methods for restoring fast axonal transport in a cell affected by oligomeric amyloid beta and for treating an oligomeric amyloid beta-mediated disease such as Alzheimer's disease using a Casein Kinase 2 inhibitor and, in some embodiments, a Glycogen Synthase Kinase 3 inhibitor. | 12-15-2011 |
| 20110311549 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 12-22-2011 |
| 20110318359 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN - The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor. | 12-29-2011 |
| 20120082676 | METHODS FOR PREVENTING AND TREATING ANGIOEDEMA - One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. | 04-05-2012 |
| 20120093828 | VACCINE COMPOSITIONS AND METHODS FOR TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES - The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant. | 04-19-2012 |
| 20120093829 | NEW METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies. | 04-19-2012 |
| 20120114660 | Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family - Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism. | 05-10-2012 |
| 20120177656 | Compounds and Methods for the Modulation of Sulfilimine Bond Formation - Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides | 07-12-2012 |
| 20120213794 | AX213 AND AX132 PSCK9 ANTAGONISTS AND VARIANTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 08-23-2012 |
| 20120219557 | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies. | 08-30-2012 |
| 20120219558 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9) are disclosed. Said antagonists are effective in the inhibition of PCSK9 function and thereby provide compositions of matter useful for the treatment of conditions associated with PCSK9 activity. The present invention further discloses nucleic acids encoding PCSK9 antagonists as well as methods of making and using PCSK9 antagonists. | 08-30-2012 |
| 20120258115 | THERAPEUTIC FORMULATIONS CONTAINING VENOM OR VENOM ANTI-SERUM EITHER ALONE OR IN COMBINATION FOR THE THERAPEUTIC PROPHYLAXIS AND THERAPY OF NEOPLASMS - A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent. | 10-11-2012 |
| 20120282267 | CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN - The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer. | 11-08-2012 |
| 20130004504 | METHOD OF MODULATING PHENYLALANINE HYDROXYLASE STRUCTURE AND FUNCTION - A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms under four conditions, wherein the method comprising: applying to the multimeric protein a composition comprising a compound adapted to affect formation of an active form of the multimeric protein; associating the composition with an active form of the multimeric protein; and promoting the multimeric protein to assemble into the active form, thereby affecting the multimeric protein to form the active form, wherein the multimeric protein is phenylalanine hydroxylase. | 01-03-2013 |
| 20130017207 | CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS - Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix. | 01-17-2013 |
| 20130022611 | METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR - The invention provides methods and compositions for modulating hepsin activity and the uPA/plasmin pathway, in particular by regulating pro-uPA activation by hepsin. | 01-24-2013 |
| 20130095113 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS - The present disclosure provides methods for treating neurological disorders, generally involving modulating protein kinase D1 (PKD1) activity levels in a neuron or glial cell in an individual in need thereof. The present disclosure provides antibodies specific for PKD1. The present disclosure provides a genetically modified non-human mammal deficient in PKD1 activity. | 04-18-2013 |
| 20130171163 | Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis - The present invention relates to the regulation of angiogenesis and arteriogenesis by leukocyte antigen-related protein tyrosine phosphatase (LAR). The invention further relates to the use of inhibitors of LAR expression and/or activity to stimulate angiogenesis and/or arteriogenesis. | 07-04-2013 |
| 20130243784 | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) - The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. | 09-19-2013 |
| 20130273062 | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF - Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists. | 10-17-2013 |
| 20130280269 | Manipulation of HSP70 and IRE1Alpha Protein Interactions - The present invention relates to methods that manipulate the level of interaction between the proteins Hsp70 and IRE1α. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases. | 10-24-2013 |
| 20130302346 | ANTIBODIES THAT BIND NOTUM PECTINACETYLESTERASE - Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone. | 11-14-2013 |
| 20140030270 | METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS - The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described. | 01-30-2014 |
| 20140093513 | METHODS OF LOWERING PROPROTEIN CONVERSATE SUBTILISIN/KEXIN TYPE 9 (PCSK9) - The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases. | 04-03-2014 |
| 20140099323 | METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies. | 04-10-2014 |
| 20140178399 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS - Certain embodiments are directed to compositions and methods of inhibiting pathogenic bacterial infection involving ADAMIO comprising administering an effective amount of a metalloprotease inhibitor to a patient. Certain embodiments are directed to method of inhibiting Staphylococcal infection comprising administering an effective amount of a metalloprotease inhibitor to a patient. Other embodiments concern methods of inhibiting infection by a bacteria from the genus | 06-26-2014 |
| 20140294854 | TARGET DIRECTED TO ADIPOCYTES, METHODS AND ASSAYS FOR TREATMENT OF OBESITY - The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject. | 10-02-2014 |
| 20140314787 | Treatment for neurodegenerative diseases - The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject a therapeutically effective amount of a modulator of said endoplasmic reticulum protein retrotranslocation machinery and/or of VCP. | 10-23-2014 |
| 20140341927 | ANTIBODIES AND THEIR USE IN THE TREATMENT, PREVENTION AND DIAGNOSIS OF A DISEASE ASSOCIATED WITH SOD1 ABNORMALITIES - The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human. | 11-20-2014 |
| 20140348850 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN - The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor. | 11-27-2014 |
| 20150044226 | Anti-Phospholipase D4 Antibody - A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof. | 02-12-2015 |
| 20150050285 | Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates - Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or antifolates. | 02-19-2015 |
| 20150132317 | METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA - Methods and compositions for treating neuroblastoma are disclosed. | 05-14-2015 |
| 20150147338 | GALACTO-RHAMNOGALACTURONATE COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED INDUCIBLE NITRIC OXIDE SYNTHASE - Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. | 05-28-2015 |
| 20150306218 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA - The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption. | 10-29-2015 |
| 20150335615 | CHOLESTEROL-LOWERING COMPOUNDS IN COMBINATION WITH LIPID METABOLISM-ALTERING COMPOUNDS OF NON-ABSORBABLE SUGARS, COMPOUNDS THAT CONVERT NH3 TO NH4+, OR HYDROGEN-GENERATING COMPOUNDS FOR THE TREATMENT OF HIGH CHOLESTEROL AND INFLAMMATION - A composition for treating high cholesterol, including synergistically effective amounts of a cholesterol-lowering agent and a lipid metabolism-altering compound chosen from a non-absorbable sugar, a compound that converts NH3 to NH4+, a hydrogen-generating compound, and combinations thereof. A composition for treating high cholesterol, including synergistically effective amounts of a statin chosen from atorvastatin, cerivastatin, fluvastain, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and lactulose. A method of lowering cholesterol by administering a synergistically effective amount of the composition to an individual, and lowering cholesterol in the individual. | 11-26-2015 |
| 20150342943 | METHODS OF TREATING LIVER DISEASE - The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ASK1 inhibitor, optionally in combination with a LOXL2 inhibitor, to a patient in need thereof. | 12-03-2015 |
| 20150344588 | MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies. | 12-03-2015 |
| 20150352094 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES - The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate, and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate and another therapeutic agent. | 12-10-2015 |
| 20160096899 | METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE SALT-STIMULATED LIPASE (BSSL) ANTIBODIES - It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies. | 04-07-2016 |
| 20160137745 | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) - The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy. | 05-19-2016 |
| 20160152732 | ANTIBODIES DIRECTED TO RICIN TOXIN | 06-02-2016 |
| 20160251447 | ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE | 09-01-2016 |
| 20220135702 | NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION - An embodiment provides a method for preventing the transmission of Covid-19, including: preparing a composition comprising an ACE2 monoclonal antibody, a Neuropilin-1 antibody, an antibody to the spike protein of Sars-CoV-2, a vegetable oil, and a saline solution; and spraying the composition in a nasal cavity of a patient. Other aspects are described and claimed. | 05-05-2022 |
